brexucabtagene autoleucel CAR-T
Selected indexed studies
- Impact of Manufacturing Procedures on CAR T Cell Functionality. (Front Immunol, 2022) [PMID:35493513]
- Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. (J Clin Oncol, 2023) [PMID:36753699]
- The present and future of CAR T-cell therapy for adult B-cell ALL. (Blood, 2025) [PMID:39316713]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Impact of Manufacturing Procedures on CAR T Cell Functionality. (2022) pubmed
- Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. (2023) pubmed
- The present and future of CAR T-cell therapy for adult B-cell ALL. (2025) pubmed
- Brexucabtagene Autoleucel. (2006) pubmed
- Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. (2023) pubmed
- T cell malignancies after CAR T cell therapy in the DESCAR-T registry. (2025) pubmed
- CAR T Cells. (2021) pubmed
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. (2021) pubmed
- Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma. (2022) pubmed
- The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL. (2024) pubmed